Search
Adenine
go.drugbank.com/drugs/DB00173ApprovedInvestigationalNutraceuticalA purine base and a fundamental unit of adenine nucleotides.
Mixtures: ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic), ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Hydralazine
go.drugbank.com/drugs/DB01275ApprovedInvestigational[A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications. … [A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.
Categories: Arteriolar Smooth Muscle, Agents Acting OnVoxelotor
go.drugbank.com/drugs/DB14975Approved[T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition … This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India.
Vosoritide
go.drugbank.com/drugs/DB11928ApprovedInvestigational[A242277] It results from a gain-of-function missense mutation in _FGFR3_ that results in a dramatic suppression of bone growth, both in volume and in length. … [L39229] It was approved for use under the brand name Voxzogo (BioMarin Pharmaceutical Inc.) in the EU in August 2021 and the US in November 2021,[L39245,L39241] becoming the first pharmacological intervention
Abiraterone
go.drugbank.com/drugs/DB05812ApprovedInvestigationalAbiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis … [L40968, L40193, L47740, L47745] and when used in combination with niraparib, BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).
Trametinib
go.drugbank.com/drugs/DB08911ApprovedInvestigational[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. … [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014.
Influenza A virus A/Michigan/45/2015 X-275 (H1N1) hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14422ApprovedInvestigationalInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Efluelda Tetra Injektionssuspension in einer Fertigspritze, VAXİGRİP 0,5 ML IM/SC ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR , 10 ADETSimoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedSimoctocog alfa is a fourth-generation BDD FVIII product made in the human embryonic kidney (HEK) cell line. … Full human post-translational modifications via elimination of potentially immunogenic glycosylation patterns found in non-human cell lines led to decreased immunogenicity and longer half-life [A31525]
Larotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigationalan important role in tumor cell growth and survival. … of cell growth in tumors that overexpress Trk.
Amivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigational[A235103,A235123] Patients with NSCLC with exon 20 insertion mutations in EGFR do not respond to tyrosine kinase inhibitors, and were generally treated with platinum-based therapy. … FDA approved the subcutaneous formulation, RYBREVANT FASPRO™, across all existing and expanded indications of amivantamab, including its use as a first-line, chemotherapy-free combination regimen with